ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.7
(-1.32%)
TWD 18.7
(-1.32%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.18 Billion TWD | -2.39% |
| 2022 | 3.26 Billion TWD | 18.16% |
| 2021 | 2.76 Billion TWD | -10.4% |
| 2020 | 3.08 Billion TWD | 6.57% |
| 2019 | 2.89 Billion TWD | -17.92% |
| 2018 | 3.52 Billion TWD | 0.22% |
| 2017 | 3.51 Billion TWD | -12.76% |
| 2016 | 4.03 Billion TWD | 1.91% |
| 2015 | 3.95 Billion TWD | -3.48% |
| 2014 | 4.09 Billion TWD | -19.46% |
| 2013 | 5.08 Billion TWD | 11.28% |
| 2012 | 4.57 Billion TWD | 15.65% |
| 2011 | 3.95 Billion TWD | 1.61% |
| 2010 | 3.89 Billion TWD | 2.05% |
| 2009 | 3.81 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 883.22 Million TWD | -21.36% |
| 2024 Q2 | 762.35 Million TWD | -13.68% |
| 2024 Q3 | 724.22 Million TWD | -5.0% |
| 2023 Q2 | 754.9 Million TWD | 16.42% |
| 2023 Q4 | 1.12 Billion TWD | 70.28% |
| 2023 Q3 | 659.58 Million TWD | -12.63% |
| 2023 Q1 | 648.43 Million TWD | -36.17% |
| 2023 FY | 3.18 Billion TWD | -2.39% |
| 2022 Q3 | 704.71 Million TWD | -12.52% |
| 2022 FY | 3.26 Billion TWD | 18.16% |
| 2022 Q2 | 805.53 Million TWD | 9.16% |
| 2022 Q1 | 737.93 Million TWD | 2.59% |
| 2022 Q4 | 1.01 Billion TWD | 44.15% |
| 2021 Q3 | 654.23 Million TWD | -12.49% |
| 2021 FY | 2.76 Billion TWD | -10.4% |
| 2021 Q1 | 641.13 Million TWD | -26.64% |
| 2021 Q2 | 747.63 Million TWD | 16.61% |
| 2021 Q4 | 719.33 Million TWD | 9.95% |
| 2020 Q2 | 908.08 Million TWD | 67.38% |
| 2020 Q4 | 873.99 Million TWD | 15.25% |
| 2020 FY | 3.08 Billion TWD | 6.57% |
| 2020 Q3 | 758.32 Million TWD | -16.49% |
| 2020 Q1 | 542.52 Million TWD | -33.8% |
| 2019 Q2 | 617.57 Million TWD | -20.01% |
| 2019 Q4 | 819.55 Million TWD | 19.89% |
| 2019 FY | 2.89 Billion TWD | -17.92% |
| 2019 Q3 | 683.61 Million TWD | 10.69% |
| 2019 Q1 | 772.04 Million TWD | -10.19% |
| 2018 FY | 3.52 Billion TWD | 0.22% |
| 2018 Q4 | 859.66 Million TWD | 5.13% |
| 2018 Q3 | 817.7 Million TWD | -17.04% |
| 2018 Q2 | 985.6 Million TWD | 14.43% |
| 2018 Q1 | 861.28 Million TWD | -3.77% |
| 2017 Q3 | 848.82 Million TWD | -0.51% |
| 2017 FY | 3.51 Billion TWD | -12.76% |
| 2017 Q2 | 853.15 Million TWD | -7.21% |
| 2017 Q1 | 919.48 Million TWD | -8.28% |
| 2017 Q4 | 895.01 Million TWD | 5.44% |
| 2016 Q1 | 1.02 Billion TWD | -0.81% |
| 2016 FY | 4.03 Billion TWD | 1.91% |
| 2016 Q4 | 1 Billion TWD | 1.1% |
| 2016 Q3 | 991.62 Million TWD | -2.31% |
| 2016 Q2 | 1.01 Billion TWD | -0.66% |
| 2015 Q2 | 963.09 Million TWD | -1.63% |
| 2015 FY | 3.95 Billion TWD | -3.48% |
| 2015 Q1 | 979.05 Million TWD | 15.14% |
| 2015 Q4 | 1.03 Billion TWD | 4.8% |
| 2015 Q3 | 982.94 Million TWD | 2.06% |
| 2014 Q4 | 850.31 Million TWD | -15.18% |
| 2014 Q3 | 1 Billion TWD | -12.66% |
| 2014 Q2 | 1.14 Billion TWD | 4.61% |
| 2014 FY | 4.09 Billion TWD | -19.46% |
| 2014 Q1 | 1.09 Billion TWD | -17.15% |
| 2013 Q4 | 1.32 Billion TWD | 6.82% |
| 2013 FY | 5.08 Billion TWD | 11.28% |
| 2013 Q1 | 1.18 Billion TWD | -15.57% |
| 2013 Q2 | 1.33 Billion TWD | 12.9% |
| 2013 Q3 | 1.23 Billion TWD | -7.38% |
| 2012 Q2 | 912.8 Million TWD | -6.02% |
| 2012 Q1 | 971.27 Million TWD | -14.03% |
| 2012 Q4 | 1.4 Billion TWD | 9.36% |
| 2012 Q3 | 1.28 Billion TWD | 40.68% |
| 2012 FY | 4.57 Billion TWD | 15.65% |
| 2011 Q4 | 1.12 Billion TWD | 6.21% |
| 2011 FY | 3.95 Billion TWD | 1.61% |
| 2011 Q1 | 796.03 Million TWD | -27.53% |
| 2011 Q2 | 964.03 Million TWD | 21.1% |
| 2011 Q3 | 1.06 Billion TWD | 10.34% |
| 2010 Q3 | 1.1 Billion TWD | 0.0% |
| 2010 FY | 3.89 Billion TWD | 2.05% |
| 2010 Q4 | 1.09 Billion TWD | -0.18% |
| 2009 FY | 3.81 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Grape King Bio Ltd | 10.63 Billion TWD | 70.036% |
| Standard Chem & Pharm CO., LTD. | 6.23 Billion TWD | 48.939% |
| Maywufa Company Ltd. | 1.3 Billion TWD | -144.947% |
| Lotus Pharmaceutical Co., Ltd. | 16.95 Billion TWD | 81.212% |
| LIWANLI Innovation Co., Ltd. | 38.88 Million TWD | -8093.183% |
| YungShin Global Holding Corporation | 7.02 Billion TWD | 54.665% |
| PhytoHealth Corporation | 162.48 Million TWD | -1860.799% |
| SCI Pharmtech, Inc. | 1.2 Billion TWD | -164.59% |
| Formosa Laboratories, Inc. | 4.36 Billion TWD | 26.932% |
| PharmaEssentia Corporation | 5.1 Billion TWD | 37.596% |
| Bora Pharmaceuticals Co., LTD. | 14.2 Billion TWD | 77.563% |